Literature DB >> 32423638

From ground-glass opacities to pulmonary emboli. A snapshot of the evolving role of a radiology unit facing the COVID-19 outbreak.

N Flor1, M Tonolini2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32423638      PMCID: PMC7205649          DOI: 10.1016/j.crad.2020.04.009

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


× No keyword cloud information.
Sir—The aim of this letter is to report what is currently happening in our Radiology Department at a tertiary infectious disease hospital in Milan, a hotspot for COVID-19, 2 months after the outbreak of the epidemic. The early phase was highly critical, and we had to find ways to manage both suspected and confirmed cases, which involved separating them from patients undergoing imaging tests for other reasons such as oncological staging or follow-up. At the time, promptness of action was favoured amongst clinicians, and in agreement with the most recent consensus statements , , computed tomography (CT) was not used as a screening test, but reserved for selected symptomatic patients. As a result, most suspected or confirmed COVID-19 patients were examined using chest radiography, thus minimising patient radiation exposure and infection transmission to the radiology staff and uninfected patients. In the course of time, about a month after the epidemic outbreak, we noticed a sudden rise in requests for CT, mostly related to CT angiography (CTA) studies to exclude acute pulmonary embolism (PE). Based on our experience of 30 consecutive CTA examinations performed in confirmed COVID-19 patients, the prevalence of PE is approximately 35%, with peripheral branch preponderance. Preliminary data indicate that approximately 5–10% of COVID-19 patients who require mechanical ventilation suffer from acute PE or deep venous thromboembolism (DVT). The probability is higher in those with signs of DVT, inexplicable hypotension or tachycardia, worsening respiratory status, or risk factors for thrombosis. The rate of micro-PE is probably even higher, as suggested by unreleased autopsy results. As undiagnosed or untreated PE may negatively affect patient outcome, empirical therapeutic anticoagulation has been recommended; however, considering the lack of evidence regarding improvement and the risk of major bleeding, CTA should be used to confirm this diagnosis and to support any decision to start therapeutic anticoagulation. Another clinical scenario that is progressively causing an increase in CT requests is pulmonary fibrosis. In fact, COVID-19 patients, particularly those recovering from a period in the intensive care unit, are at risk of developing fibrosis. In conclusion, after having faced preparedness and diagnostic procedures, radiology departments should also be prepared to deal with these two clinical issues.

Conflict of interest

The authors declare no conflict of interest.
  4 in total

Review 1.  From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia.

Authors:  Seth J Kligerman; Teri J Franks; Jeffrey R Galvin
Journal:  Radiographics       Date:  2013 Nov-Dec       Impact factor: 5.333

2.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Marco Marietta; Walter Ageno; Andrea Artoni; Erica De Candia; Paolo Gresele; Marina Marchetti; Rossella Marcucci; Armando Tripodi
Journal:  Blood Transfus       Date:  2020-04-08       Impact factor: 3.443

3.  The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society.

Authors:  Geoffrey D Rubin; Christopher J Ryerson; Linda B Haramati; Nicola Sverzellati; Jeffrey P Kanne; Suhail Raoof; Neil W Schluger; Annalisa Volpi; Jae-Joon Yim; Ian B K Martin; Deverick J Anderson; Christina Kong; Talissa Altes; Andrew Bush; Sujal R Desai; Onathan Goldin; Jin Mo Goo; Marc Humbert; Yoshikazu Inoue; Hans-Ulrich Kauczor; Fengming Luo; Peter J Mazzone; Mathias Prokop; Martine Remy-Jardin; Luca Richeldi; Cornelia M Schaefer-Prokop; Noriyuki Tomiyama; Athol U Wells; Ann N Leung
Journal:  Radiology       Date:  2020-04-07       Impact factor: 11.105

4.  An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement.

Authors:  J C L Rodrigues; S S Hare; A Edey; A Devaraj; J Jacob; A Johnstone; R McStay; A Nair; G Robinson
Journal:  Clin Radiol       Date:  2020-03-23       Impact factor: 2.350

  4 in total
  3 in total

1.  COVID-19 classification by CCSHNet with deep fusion using transfer learning and discriminant correlation analysis.

Authors:  Shui-Hua Wang; Deepak Ranjan Nayak; David S Guttery; Xin Zhang; Yu-Dong Zhang
Journal:  Inf Fusion       Date:  2020-11-13       Impact factor: 12.975

2.  Diagnostic performance of chest radiography in high COVID-19 prevalence setting: experience from a European reference hospital.

Authors:  Nicola Flor; Lorenzo Saggiante; Anna Paola Savoldi; Renato Vitale; Giovanni Casazza; Paolo Villa; Anna Maria Brambilla
Journal:  Emerg Radiol       Date:  2021-07-03

3.  Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study.

Authors:  Kristoffer Grundtvig Skaarup; Mats Christian Højbjerg Lassen; Caroline Espersen; Jannie Nørgaard Lind; Niklas Dyrby Johansen; Morten Sengeløv; Alia Saed Alhakak; Anne Bjerg Nielsen; Kirstine Ravnkilde; Raphael Hauser; Liv Borum Schöps; Eva Holt; Henning Bundgaard; Christian Hassager; Reza Jabbari; Jørn Carlsen; Ole Kirk; Uffe Bodtger; Matias Greve Lindholm; Lothar Wiese; Ole Peter Kristiansen; Emil Schwarz Walsted; Olav Wendelboe Nielsen; Birgitte Lindegaard; Niels Tønder; Klaus Nielsen Jeschke; Charlotte Suppli Ulrik; Morten Lamberts; Pradeesh Sivapalan; Jannik Pallisgaard; Gunnar Gislason; Kasper Iversen; Jens Ulrik Stæhr Jensen; Morten Schou; Søren Helbo Skaarup; Elke Platz; Tor Biering-Sørensen
Journal:  J Ultrasound       Date:  2021-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.